Last update Jan. 3, 2023
It is a tertiary amine with antimuscarinic and antispasmodic actions that is used for the symptomatic treatment of parkinsonism and drug-induced extrapyramidal dystonias. Oral or intravenous administration.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic data: very high percentage of protein binding (DrugBankl) and wide volume of distribution (Whiteman 1985), make it highly unlikely that significant quantities will pass into breast milk.
No changes in prolactin levels have been observed with the use of this medicine. (Johnstone 1983)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM